Gene Query: XAGE1A

Dataset Description Geneva Score
Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone [HCT RNA-Seq] 186.88
Gene expression changes associated with resistance to tagraxofusp (SL-401) 62.13
SAM68 is required for regulation of Pumilio by the NORAD long noncoding RNA 48.21
The E3 ubiquitin ligase HectD1 suppresses EMT and metastasis by targeting the +TIP protein ACF7 for degradation 47.06
Pharmacologic inhibition of STAT5 in AML 45.86
Gene expression alterations associated with acquired-resistance to the CDK4/6 inhibitor palbociclib [Palbociclib resistance_RNASeq] 40.5
Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer. 40.09
Metastasis in triple-negative breast cancer 40.09
hTERT promotes cell adhesion and migration independent of telomerase activity 37.62
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence 35.16
Non-synchronized cell cycle transcriptomics in U2OS and HeLa cancer cells 32.29
Enriched EWSR1 and EWS-FLI1 RNA-seq of HNRNPH1-silenced TC32 Ewing sarcoma and 293T human embryonic kidney cells. 26.08
Transcriptome analysis of PC9 cells with gefitinib or/and hypoxia treatment and comparison with gefitinib resistant PC9 cells and ALDH positive PC9 cells 26.02
SRSF2 mutations impair hematopoiesis and alter exon recognition 25.27
Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer 24.88
3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations 24.71
Fbxo32 mediated gene expression program underlies EMT and metastasis 24.65
EZHIP constrains Polycomb Repressive Complex 2 activity in germ cells (RNA-Seq) 23.42
EZHIP constrains Polycomb Repressive Complex 2 activity in germ cells 23.42
Genome-wide profiling of siRNA targeting EWS-FLI1 in TC32 Ewing sarcoma cell line 22.66
Identification of ZEB1-regulated gene expression changes in HCC827 human lung adenocarcinoma cells 22.62
Transcriptome profiling of 5 human adenocarcinoma cell lines 22.58
The stress granule transcriptome reveals principles of mRNA accumulation in stress granules. 22.54
RNA-Seq in two Ewing sarcoma cell lines: A673 and SKNMC 22.26
Reprogramming of Tumor-infiltrating Immune Cells in Early Stage of NSCLC 21.55
Gene expression profiling study by RNA-seq for identifying genes associated with epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 20.52
Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 20.52
Neonatal and adult human testis defined at the single-cell level 18.43
RNA-Seq of over-expression and knockdown of the lncRNA SLNCR1 in melanoma cells 18.2
RNA-Seq Analysis of Anacardic Acid Treated MCF7 and MDA-MB-231 Breast Cancer Cell Lines 17.87
Expression changes in melanoma cell lines under BRAFi treatment timepoints [RNA-Seq.CellLine.batch4] 17.84
Gene Expression Analysis of Melanoma Cells Treated with 6-Thio-dG In Vitro 17.77
Comparison of expression profiles of APP-depleted prostate cancer cells (LNCaP) 17.3
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies 17.23
RNA-seq of cells with TET1 knockout 16.84
Nucleoporin-mediated regulation of cell identity genes 16.23
CDK12 regulates alternative last exon mRNA splicing and promotes invasion of a breast cancer cell line 16.18
Evolution of an lncRNA leads to a primate specific modulation of alternative splicing 16.07
Inhibition of TNBC metastasis by Gpx1 15.61
Genome-wide chromatin analysis of Ewing sarcoma (RNA-seq) 15.37
Genome-wide chromatin analysis of Ewing sarcoma 15.37
ZFR coordinates crosstalk between RNA decay and transcription in innate immunity 15.29
ZBTB10 binds the telomeric variant repeat TTGGGG and interacts with TRF2 [RNA-Seq] 14.65
ZBTB10 binds the telomeric variant repeat TTGGGG and interacts with TRF2 14.65
ZRANB2 and SYF2 mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin 14.35
Chromatin Topology Reorganization and Transcription Repression by PML/RARα in Acute Promyeloid Leukemia 14.18
Chromatin Topology Reorganization and Transcription Repression by PML/RARα in Acute Promyeloid Leukemia (RNA-seq) 14.18
ZBTB48 is both a vertebrate telomere-binding protein and a transcriptional activator 13.81
ZBTB48 is both a vertebrate telomere-binding protein and a transcriptional activator [RNA-seq] 13.81
A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation 13.74
A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation [human cell line RNA-seq] 13.74
Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence 13.56
The lung-enriched p53 mutants V157F and R158L/P regulate a novel transcriptome in lung cancer 13.48
Global transcriptional profiling changes upon knockout of USP22 in human Non-small cell lung cancer cells 13.15
Coordinate regulation of alternative pre-mRNA splicing events by the human RNA chaperone proteins hnRNPA1 and DDX5 12.97
The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma 12.24
Gene expression profile of HGC27 and LMSU gastric cancer cell p53 KO and KD 11.74
Modulation of Indoleamine 2, 3-dioxygenase 1 Expression by Activated Human T cells in Breast Cancer Cells is Controlled by DNA Promoter Methylation 11.67
Global transcriptional profiling changes upon knockdown of G9a in human non-small cell lung cancer cells 11.47
RNA Seq data: A375, A375R, A375DR vorinostat treated, and biopy samples from patients pre- and post- treated with Vorinostat 11.45
An acquired vulnerability of drug resistant melanoma with therapeutic potential 11.45
METTL3 promotes translation in human cancer cells 11.36
Comprehensive comparative analysis of 5’ end RNA sequencing methods 11.32
Potential signaling pathways and gene signatures associated with brain metastases in NSCLC patients 11.31
Decoding breast cancer tissue-stroma interactions using species-specific sequencing 11.17
Cell-to-cell variation in defective virus expression and effect on host response during influenza virus infection 10.8
GDF6-induced BMP signaling reawakens a neural crest identity in melanoma to prevent cell death and differentiation 10.39
Differential gene expression of human melanoma cells [RNA-seq] 10.39
The Human Testis Cell Atlas via Single-cell RNA-seq (Healthy men scRNA-seq data set) 10.33
Activation of HOTTIP lncRNA perturbs HSC function leading to AML like disease 10.17
RNA-Seq analysis of breast cancer cells after shikonin treatment 10.16
Muscleblind-like 1 suppresses breast cancer metastatic colonization and stabilizes metastasis suppressor transcripts 10.12
MBNL1-dependent modulation of gene expression in MDA-MB-231 breast cancer cells 10.12
The flightless I protein is involved in the genome-wide mRNA post-transcriptional regulation in lung carcinoma cells 10.04
Comparison between THP-1 cells obtained from either ATCC or DSMZ biorepository 9.69
EWS-Fli and LNC regulated genes in comparison to GFP samples 9.63
The anti-leukemic effect of R-2HG depends on its acting as an m6A mRNA modifier-RNA Seq-PBS / R-2HG treatment 9.4
Targeted inhibition of STAT/TET1 axis as a potent therapeutic strategy for acute myeloid leukemia 9.33
Small molecule inhibition of ERK dimerization prevents tumorigenesis by Ras-ERK pathway oncogenes 9.25
Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference [RNA-Seq] 9.13
Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference 9.13
Accurate annotation of human protein-coding small open reading frames 9.1
A Druggable TCF4- and BRD4-dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm (RNA-Seq) 9.05
Insulin induced alterations in chromatin acetylation and transcriptome in triple negative breast cancer cells 8.84
Gene Expression of Breast Cancer Cell Lines Across Biomaterial Platforms 8.83
Adipocyte-derived lipids mediate melanoma progression via FATP proteins 8.75
Genome-wide RNA-seq from GALNT14-depleted and GALNT14 overexpressing MDA-MB-231 LM2 and Par cells 8.7
BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage 8.68
BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) 8.68
Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer 8.39
Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer [RNA-Seq] 8.39
Two dimensional and extracellular matrix based three-dimensional cultures of lung and breast cancer cells 7.84
Gene expression profiling in two dimensional and extracellular matrix based three-dimensional cultures of lung and breast cancer cells 7.84
Differential gene expression profiles in imatinib-resistant cell lines 7.75
RNA-seq of H1299 cells in which either PRKCI or SOX2 was silenced by validated lentiviral shRNA constructs 7.61
Histone H3 Lysine4 Acetylation-Methylation Dynamics Define Breast Cancer Subtypes 7.52
Histone H3 lysine 4 acetylation-methylation dynamics define breast cancer subtypes [RNA-seq] 7.52
Effect of Hotair overexpression in human breast cancer cell lines 7.45
EZH2 inhibitor-mediated transcriptional profiling in prostate cancer cells [RNA-seq] 7.35
Distinct changes in transcriptional profiles and epigenetic patterns mediated by EZH2 inhibitors in sensitive and insensitive prostate cancer cells 7.35
Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma: RNA-sequencing of PEL cell lines during KSHV reactivation 7.17
The effect of Abl kinases on non-small cell carcinoma global transcriptome 7.14
A Surveillance System of Active Enhancers by a RACK7-histone Demethylase Complex (RNA-Seq I) 7.1
APT1 regulates the asymmetric partitioning of Notch and Wnt signaling during cell division 6.92
HDAC and NFκB antagonists synergistically inhibit growth and metastatic dissemination of MYC-driven medulloblastoma 6.76
Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing 6.71
AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition 6.7
Tafazzin Regulates Cell State by Modulating Phosphatidylethanolamine and Phosphatidylserine levels 6.51
Transcriptional profiling of MDA-MB-231 and its ρ0 cells (lacking mtDNA) after 48h arginine depletion by arginine deiminase (ADI). 6.49
RNA seq_PDX2_SHP099 6.49
KDM1A confers invasive and metastatic attributes in lung adenocarcinoma by modulating a non-canonical Integrin ß3-KRAS signaling pathway 6.46
A damaged genome's transcriptional landscape through multilayered expression profiling around in situ-mapped DNA double-strand breaks 6.44
Human co-transcriptional splicing kinetics and coordination revealed by direct nascent RNA sequencing 6.43
Sequencing of messenger RNAs with N6-methyladenosine modifications in acute myeloid leukemia (AML) with and without forced expression of FTO 6.41
HLA peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy 6.2
RNA-seq and m6A-seq of AML cells with FTO knockdown or inhibition 5.86
RNAseq to determine gene expression changes following depletion of SETDB1 in THP-1 AML Cells 5.85
Polysome-associated mRNA profiling of cancer cells in response to CXCL12 and IGF1 5.82
Next Generation Sequencing Quantitative Analysis of Wild Type and AML1-ETO Related Fusion Circular RNA (F-CircAE) Knockdown Kasumi-1 Cells Transcriptomes 5.8
Specific inhibition of DPY30 activity by peptides suppresses blood cancer cell growth 5.76
Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer 5.74
TT-Seq captures the human transient transcriptome 5.74
The MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in MLLr AML 5.56
PR isoform-specific ER and PR chromatin binding and gene expression observed in-vitro in breast cancer cells. 5.52
Gene expression analysis of ER+ and ER- breast cancer cell lines with acquired resistance to palbociclib 5.36
Transcriptomic responses to Ivacaftor and prediction of Ivacaftor clinical responsiveness 5.28
A transcriptome dataset revealing the molecular features of breast cancer stem cells 5.25
Transcriptome of EBV-infected gastric cancer cell lines 5.25
Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis 5.17
Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis [MultiDisease] 5.09
A Surveillance System of Active Enhancers by a RACK7-histone Demethylase Complex 5.01
RNA sequencing of GLO1-depleted MDA-MB-231 breast cancer cells 4.98
Differentiation enhances Zika virus infection in neuronal brain cells 4.92
RNA seq_A375 gSMARCB1 + A549 etoposide, Aurora kinases inhibitors treated 4.91
Quantitative Analysis of negative control and overexpression-TRIB1 in PC3 and DU145 Transcriptomes 4.75
Genome-wide CRISPR-Cas9 screen identifies druggable synthetic lethality between LSD1 and MTORC1 in MLL-translocated AML 4.72
CASZ1 directly regulates expression of myogenic genes through regional epigenetic modifications to induce muscle and rhabdomyosarcoma cell differentiation 4.72
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma 4.51
Elucidating the microRNA-203 specific biological processes in glioblastoma cells from comprehensive high-throughput RNA-sequencing transcriptome profiling 4.5
Vitamin C Promotes Apoptosis in Breast Cancer Cells by Increasing TRAIL Expression 4.41
The effects of chemokines CCL2/7 on MDA-MB-231-FOXC1 cells 4.39
Carcinoma-astrocyte gap junctions promote brain metastasis by cytosolic dsDNA response transfer 4.36
Quantitative analysis of bi-modal binding of BET proteins at promoters predicts I-BET sensitivity 4.32
Differetially expressed genes after hTR overexpression in U2OS cells 4.26
Integrated analyses of early responses to radiation in glioblastoma identify new alterations in RNA processing and candidate targets to improve treatment outcomes 4.23
RNA sequencing of primary human platelets and in vitro cell lines 4.2
CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer 4.06
JQ1 +/- Vemurafenib in BRAF mutant melanoma (A375) 4.04
Functional Significance of U2AF1 S34F Mutation in Lung Adenocarcinomas 4.0
BRG1 governs Glucocorticoid Receptor interactions with chromatin and pioneer factors across the genome 3.82
Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer 3.81
Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer [RNA-Seq] 3.81
Gene expression changes upon drug withdrawal (A375/451Lu cell lines) 3.8
Club cells surviving influenza A virus infection induce temporary non-specific anti-viral immunity 3.8
Arginine methylation controls cell proliferation by integrating E2F activity with the splicing machinery (RNA-seq data set) 3.8
Arginine methylation controls cell proliferation by integrating E2F activity with the splicing machinery 3.8
Effect of Ro 08-2750 treatment on gene expression of human leukemia cell lines MOLM13 and K562 3.8
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination 3.8
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq) 3.8
Determination of a comprehensive alternative splicing regulatory network and the combinatorial regulation by key factors during Epithelial-to-Mesenchymal Transition [ESRP KD] 3.75
RNAseq of human monocyte cell line (U937-Cas9) WT or IRF2KO 3.72
Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer 3.7
Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy 3.7
TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells 3.66
TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells [RNA-seq] 3.66
Ribosome profiling upon inhibition of eIF4A 3.57
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia 3.55
Gene expression profiling associated with knockdown of RNF20 in human normal and malignant lung epithelial cell lines 3.54
RNAseq data from SCCOHT1 and OVCAR8 ovarian cancer cells treated with BET inhibitors 3.53
An integrative analysis of non-coding regulatory DNA variations associated with autism 3.5
Transcriptomic analysis to functionally map the intrinsically disordered domain of EWS/FLI [Experiment 1] 3.48
Effect of selective glucocorticoid receptor modulation (SGRM) on gene expression in human prostate cancer cell lines 3.46
RNA-seq melanoma 3.45
Non-coding regions are the main source of tumor-specific antigens [human] 3.43
Non-coding regions are the main source of tumor-specific antigens 3.43
ML29755 RNA-seq data 3.41
IDH3a KO RNA-seq 3.39
RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas 3.32
CD97 is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function 3.31
Interactome (iCLIP) and Translatome ( Polysome profiling) of Musashi 2 (MSI2) targets in K562 3.29
Gene expression profile of melanoma cell lines after overexpression or knockdown of KPC1 3.27
AML subtype is a major determinant of the association between prognostic gene expression signatures and their clinical significance. 3.22
CRISPR-Cas9 combinatorial KO of epigenetic regulators in human ovarian cancer cells 3.18
Glutaminolysis is a metabolic dependency in FLT3 ITD Acute Myeloid Leukemia unmasked by FLT3 Tyrosine Kinase Inhibition 3.13
Gene induction by the USP6 oncogene in response to interferon 3.11
Transcriptome sequencing after MAGOHB knockdown in MAGOH-deleted or non-deleted cancer cells 3.08
RNA-sequencing of human leukemia cells and mouse hematopoietic progenitors 3.04
Genetic and pharmacological restoration of TET2 function blocks stem cell self-renewal and progression of leukemia 3.04
Expression analysis of Mebendazole treated THP-1 cells in three paired samples 3.02
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma 2.98
Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells 2.97
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells 2.95
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance 2.91
The X-linked DDX3X RNA helicase dictates translation re-programming and metastasis in melanoma 2.91
Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition 2.86
MEK inhibition rewires enhancer landscapes in RAS-driven Rhabdomyosarcoma to unlock a myogenic differentation block 2.86
RNA-seq analysis of control and Myc-induced U2OS cells 2.86
In situ CAPTURE of chromatin interactions by biotinylated dCas9 2.72
RNA-seq transcriptonal profiling in human K562 cells with or without dCas9 and sgRNAs 2.72
Anaylsis of the effect of down-regulation of the EWS-FLI1 fusion protein in Ewing Sarcoma cells by RNA-seq. 2.68
Synergy from Gene Expression and Network Mining (SynGeNet) method predicts genotype-specific synergistic drug combinations in melanoma 2.64
Transcriptome profiling of CXCR2+ neuroendocrine (NE) tumor cells purified from patients' fresh prostate adenocarcinoma 2.64
AhR activity directs BRAF inhibitors resistance in metastastic melanoma 2.61
Reprogrammed myeloid cell transcriptomes in NSCLC 2.6
The Polycomb protein BMI1 induces an invasive gene expression signature in melanoma that promotes metastasis and chemoresistance. 2.59
MARCKS and lnc-MARCKS act as inflammation regulators 2.57
Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML) 2.56
RNAseq to determine whether bidirectional transcription occurs over transposable elements following depletion of SETDB1 in THP-1 AML Cells 2.52
Preclinical model of obesity and ER-positive breast cancer 2.5
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma 2.49
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma (RNA-Seq) 2.49
CDK12 mediated transcriptional regulation in U2OS cells 2.45
Compensatory Csf2-driven macrophage activation blunts long-term efficacy of therapeutic Csf1r inhibition in breast-to-brain metastasis 2.45
Splicing and gene expression changes in human MDAM-MB231 breast cancer cells with TRA2B knockdown 2.44
Gene expression profile of HGC27 gastric cancer cell p53 KO and KD 2.44
The Human Testis Cell Atlas via Single-cell RNA-seq 2.43
Downregulation of DDX5/DDX17 and REST 2.42
Differential responses by human respiratory epithelial cell lines to respiratory syncytial virus reflect distinct patterns of infection control 2.41
Effect of low-dose sorafenib and alkylating agents in inflammation and angiogenesis in breast cancer 2.4
Alarmin S100A11 initiates a chemokine response to the human pathogen Toxoplasma gondii 2.38
Transcriptomic analysis of acute mitochondrial pyruvate carrier inhibition using UK5099 in ABL prostate cancer cells 2.37
mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues 2.36
mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues (sequencing) 2.36
Real-time observation of light-controlled transcription in living cells 2.33
Episomal HBV persistence within transcribed host nuclear chromatin compartments involves HBx 2.31
Controlling for gene expression changes in transcription factor protein networks. 2.29
Genome-wide RNA-sequencing (RNA-seq) of benign and malignant prostate cell lines without and with androgen (R1881) stimulation. 2.29
microRNAs with an AAGUGC seed motif constitute an integral part of a signaling network driving NSCLC cell proliferation 2.23
Targeting Taxane-Platin Resistant Lung Cancers with JumonjiC Lysine Demethylase Inhibitors (RNA-Seq) 2.22
Targeting Taxane-Platin Resistant Lung Cancers with JumonjiC Lysine Demethylase Inhibitors 2.22
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L 2.21
Transcriptome analysis of total RNA in human osteosarcoma cell line U2OS before and after inhibition of zinc finger protein ZNF768 2.21
ZMYND8 reads the dual histone mark H3K4me1-H3K14ac to antagonize the expression of metastasis-linked genes 2.12
Transcriptomic analysis of the effect of histone H4 K31R mutation in U2OS cells 2.1
High Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML 2.08
SMN deficiency in spinal muscular atrophy causes widespread intron retention and DNA damage 2.07
Transcriptional study of ARN8 cells treated with novel DHODH inhibitors 2.06
Diverse Compounds from Pleuromutilin Lead to a Thioredoxin Inhibitor and Inducer of Ferroptosis 2.05
Transcriptome splicing analysis in K562 cells expressing rare and private spliceosomal mutations 2.04
Gene expression profile in breast cancer cells 2.04
Genome-wide profile of cJun and p27 and gene expression profile in breast cancer cells 2.04
Finding missing proteins from epigenetically manipulated human cells 2.03
JAK dependent survival of ALK- ALCL 2.03
Human Cactin interacts with DHX8 and SRRM2 to assure efficient pre-mRNA splicing and sister chromatid cohesion. 2.02
Genome-wide Analysis of Human Constitutive Androstane Receptor (CAR) Transcriptome in Wild-type and CAR-knockout HepaRG cells 2.02
NHLRC1 re-expression in cancer cells 2.01
Gene expression by high-throughput sequencing of T47D-MTVL human breast cancer cells upon H1.4 knock-down and multiple H1 variants 1.98
SIX4 acts as a master regulator of genes associated with the malignant phenotype of non-small cell lung cancer cells 1.97
Endogenous retroviruses are a source of oncogenic enhancers in acute myeloid leukemia [RNA-Seq] 1.95
Endogenous retroviruses are a source of oncogenic enhancers in acute myeloid leukemia 1.95
Drug combination of 17-AAG and Belinostat on MDA-MB-231 breast cancer cells 1.93
Next Generation RNA Sequencing Analysis of AMPK Wild Type, AMPKα-KO and AMPKα1-2A U2OS cell Transcriptomes 1.92
RNA sequencing of MDA-MB231 and U2OS cancer cell lines exposed to the alkylating agent methyl methanesufonate (MMS) and classical chemotherapeutics  1.91
MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance (RNA-Seq) 1.9
MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance 1.9
The effect of Abl kinases,or Ponatinib challenging on breast cancer cells' global transcriptome 1.88
Targeting MTHFD2 in Acute Myeloid Leukemia 1.87
T47D xenografts treated with various combinations of ER- and PR-targeting therapies 1.83
RNA-seq of three Ewing sarcoma cell lines (A673, SK-N-MC, RDES), transfected with either siControl or siMYBL2. 1.82
Cooperation of dominant oncogenes with regulatory variants shapes clinical outcomes in pediatric cancer 1.82
Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma 1.81
Discovery and verification of liver cancer marker genes and variable scission based on second-generation sequencing data analysis 1.8
Sequencing Universal Human Reference RNA by Smart-seq and early barcoding library preparation methods 1.79
RNA-Seq of SLNCR1 over-expression in the melanoma cell line A375 1.77
TGF-b-activated LncRNA LINC00115 is a critical regulator for glioma stem-like cell tumorigenicity 1.76
TGF-β promotes genomic instability after loss of RUNX3 1.76
FMR1 reactivating treatments in Fragile X iPSC-derived neural progenitors in-vitro and in-vivo 1.75
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines 1.75
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines [RNA-seq] 1.75
KSDM1b Role in Ewing Sarcoma 1.75
Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets (RNA-seq AML development) 1.71
Persistence of stem cell metabolism in cancers as a failure of differentiation 1.71
lncRNA-PCAT1 knockdown effect on the gene expression of androgen independent LNCaP (LNCaP-AI) cell line 1.71
Role of COP1 on MAP kinase transcriptional output in melanoma 1.69
Arnica montana stimulates extracellular matrix gene expression in human macrophages differentiated to wound-healing phenotype. Tested on 5 concentrations. 1.65
PolyA-sequencing in Kelly and Kelly E9R neuroblastoma cells treated with THZ531 or DMSO 1.65
miCLIP, RNA-Seq, and Ribo-Seq in MOLM13 cells 1.65
SLAM-seq for K562 endogenous mRNA decay 1.63
GATA3-mediated chromatin reprogramming in breast cancer cells 1.61
Improved genome-wide mapping of uncapped and cleaved transcripts in eukaryotes—GMUCT 2.0 1.6
Evidence for HOXC6 as a potential molecular marker for non-small cell lung cancer 1.6
Acquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma 1.59
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer 1.57
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq) 1.57
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression 1.56
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression [RNA-seq] 1.56
Identification of Resistance Genes to BRAF Inhibitor in Melanoma by piggyBac Transposon Activation Mutagenesis Screen 1.55
RNA-seq, ChIP-seq and single cell RNA-seq of human skin Langerhans cells 1.55
Transcriptomic analysis of LSD1 1.55
IKZF1 as a Master Regulator of Immune Infiltrate Recruitment in Solid Tumors 1.51
Leukodystrophy-associated POLR3A mutations down-regulate the RNA polymerase III transcript and important regulatory RNA BC200 1.51
Transcriptional responses of melanoma cells to BRAF inhibition 1.5
The pioneer factor CEBPA modulates vitamin D signaling 1.5
Effects of transcription factor CEBPA knockdown on vitamin D target gene regulation in THP-1 cells 1.5
Adaptation of the Kinome Promotes Resistance to BET Bromodomain Inhibitors in Ovarian Cancer 1.47
CDK4/6 inhibitor resistance in prostate cancer 1.46
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-FU-Mediated Cytotoxicity in Multiple Human Cancer Types 1.46
Single-cell transcriptome of human epithelial cells reveals novel insights into early innate immune responses to influenza virus and viral antagonism 1.46
Catalogue of differentially expressed long non-coding RNAs following activation of human and mouse innate immunity 1.45
Viral determinants in H5N1 influenza A virus enable productive infection of HeLa cells 1.44
Regulation of hypoxia-inducible factor activity by ZMYND8 1.43
JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML 1.43
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) 1.42
Genome wide expression change in LCC2 and MCF-7 cells 1.42
Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer 1.42
The role of TFEB in retinoid induced differentiation of NB4 APL leukemic cells (shTFEB) 1.41
RNAseq of Breast cancer PDX samples 1.38
IQGAP3 interacts with Rad17 to activate the MRN/ATM/Chk2 signaling and promote radioresistance in lung cancer 1.36
The ZZ-type zinc finger of ZZZ3 modulates the ATAC complex-mediated histone acetylation and gene activation 1.3
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma 1.3
RNA-Seq of cKIT+ sorted cells from 16-16.5 week old fetal testes and ovaries and RNA-Seq of TRA-1-60+ H1 hESCs 1.3
Whole transcriptome splicing analysis in isogenic lung epithelial and adenocarcinoma cell lines with or without a recurrent splicing factor mutation, U2AF1 (S34F) 1.29
Dual inhibition of HDMX and HDM2 as a Therapeutic Strategy in Leukemia 1.29
MUC1-C represses the RASSF1A tumor suppressor and activated Kras signaling in human carcinoma cells 1.28
Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma engages the ER-stress response II 1.28
Cistromic re-programming by truncating GATA3 mutations promotes mesenchymal transformation in vitro, but not mammary tumour formation in mice [RNA-seq] 1.28
Cistromic re-programming by truncating GATA3 mutations promotes mesenchymal transformation in vitro, but not mammary tumour formation in mice 1.28
LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene 1.24
Differentially Expressed Genes upon Knockdown of ZRANB1 or EZH2 in LM2 Cells 1.23
A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism 1.21
PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer 1.2
RNA-seq analysis of AML cells in response to ASLAN003 1.19
Knock-down of Ror1 in MDA-MB-231 cell line decreases cell invasiveness 1.18
VAMP8 contributes to TRIM6-mediated type-I interferon antiviral response upon West Nile virus (WNV) infection 1.18
Transcriptome profiling of A2M treated A549 Cell Line Samples 1.17
Arnica montana stimulates extracellular matrix gene expression in human macrophages differentiated to wound-healing phenotype. 1.16
Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance 1.15
Transcriptome of melanoma cell lines resistant to inhibition of the MAPK pathway. 1.14
Ribosomal footprinting of MDA-Parental and MDA-LM2 1.14
A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 has a neural crest-like phenotype and is highly metastatic in vivo 1.13
mRNA sequencing of oropharyngeal cancer cell lines 1.13
Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001 1.12
Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function 1.11
Comprehensive comparative analysis of RNA sequencing methods for degraded or low input samples 1.09
Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids 1.09
Expression profile of LNCaP/AR cells with or without HNF4G expression grown for long term in charcoal stripped-serum (CSS) media 1.07
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation (RNA-Seq) 1.06
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation 1.06
Understanding the Mechanistic Contribution of Herbal Extracts in Compound Kushen Injection with Transcriptome Analysis 1.04
Nuclear HNRNPA2B1 HITS-CLIP and RNA-seq 1.03
H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [K562] 1.02
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity 1.01
Impact of DNA MMR activity on antiviral gene expression in H441 cells infected with influenza A virus 0.99
SOX17 Is a Critical Specifier of Human Primordial Germ Cell Fate 0.99
Krüppel-like Transcription Factor-10 (KLF10) Provides a Negative Feedback Mechanism to Suppress TGFβ-Induced Epithelial-to-Mesenchymal Transition [RNA-Seq] 0.98
Krüppel-like Transcription Factor-10 (KLF10) Provides a Negative Feedback Mechanism to Suppress TGFβ-Induced Epithelial-to-Mesenchymal Transition 0.98
RIG-I and MDA5 fRIP during KSHV lytic reactivation 0.98
Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells 0.97
Messenger RNA profile analysis deciphers new Esrrb responsive genes in prostate cancer cells 0.96
Genome-wide discovery of human splicing branchpoints [RNAse] 0.96
Analysis of gene expression, motif and pattern of m6A modified region and m6A enrichment level in Ocular melanoma and Melanocyte cell lines. Gene expressin analysis of METTL3 knock down in PIG1, ALKBH5 knock down and HINT2 over expression in OCM1. 0.92
HMGA1 and FOXM1 synergistically regulate a common gene network modulating angiogenesis in breast cancer 0.91
Ribo_seq (aka ribosome profiling) analysis of control and Myc-induced U2OS cells 0.91
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia 0.9
Role of BET proteins in YAP/TAZ-dependent transcription [RNA-seq 2] 0.9
Proteomics identifies a marker signature of MAPKi resistance in melanoma 0.89
RNA-Seq of SHEP TET21N cells upon Doxorubicin treatment 0.89
Fusion discovery in breast cancer cell line 0.89
RNASeq of MV4;11 cells transduced with scramble shRNA or BRD4 shRNA in combination with DMSO or SGC0946 0.88
A549 cell transcriptome responses to infection with H7N9 influenza virus 0.87
RNA-Seq with and without RNase treatment in PCa cell lines 0.87
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis 0.87
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis [Quant-Seq] 0.87
Zika virus infection reprograms global transcription of host cells to allow sustained infection 0.86
RNA-seq analysis of control and NRDE2-depleted breast cancer cells 0.83
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma 0.82
Ribosomal footprinting of CN34-Parental and CN34-LM1a 0.82
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures [RNA-seq] 0.82
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures 0.82
CSL RNA-Seq on HKC and SCC cell lines 0.81
CSL 0.81
Dexamethasone inhibits respiratory syncytial virus-driven mucus production while increasing viral replication without altering antiviral interferon signaling 0.81
The cohesin complex prevents Myc-induced replication stress 0.81
Race-specific transcriptome and Long non-coding RNA of ADT-resistant African-American prostate cancer cell models. 0.79
Promoter of lncRNA gene *PVT1* is a tumor suppressor DNA element 0.77
Next Generation Sequencing Facilitates Quantitative Analysis of Wild Type and PVT1 Knockdown by CRISPRi in MDA-MB-231 human breast cancer cell line 0.77
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [mutant MEF2C] 0.77
CENPA-Bound Genes and Transcriptional Profiling of CENPA-Depleted Prostate Cancer Cells 0.77
Transcriptional Profiling of CENPA-Depleted Prostate Cancer Cell Lines 0.77
Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells (2) 0.76
Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells 0.76
Genome-wide maps of transcriptomic and epigenomic state in melanoma cell lines 0.73
Radiation enhances melanoma response to immunotherapeutic and synergizes with benzodiazepines to promote improved anti-tumor activity 0.69
Determination of a comprehensive alternative splicing regulatory network and the combinatorial regulation by key factors during Epithelial-to-Mesenchymal Transition [RBM47 KD] 0.69
RNA deep sequencing to compare genome-wide differences between PRMT5/knockdown and control AML cells 0.67
CUREfast: Accelerating research with families 0.63
INO80 governs super-enhancer-mediated oncogenic transcription and tumor growth in melanoma 0.63
INO80 governs super-enhancer-mediated oncogenic transcription and tumor growth in melanoma [RNA-seq] 0.63
Profiling gene expression changes in ovarian cancer cells seeded on 3D organotypic culture of omentum 0.61
RNAseq analysis of ruxolitinib treated breast cancers 0.61
Neural cell adhesion molecule 1 (NCAM1; CD56) promotes leukemogenesis and confers drug resistance in acute myeloid leukemia. 0.6
Identification of alternatively spliced transcripts in brain metastatic derivatives of MDA-MB-231 breast cancer cells in response to RBM47 expression 0.58
The identification of RBM47 binding sites and RBM47-dependent alternative splicing events in brain metastatic breast cancer cells 0.58
A cell cycle-based functional screen to identify lncRNA-based cancer biomarkers 0.57
TimeLapse-seq: adding a temporal dimension to RNA sequencing through nucleoside recoding 0.57
U2AF1 mutations alter splice site recognition in hematological malignancies 0.56
RRAD, IL4I1, CDKN1A, and SERPINE1 genes are potentially co-regulated by NF-κB and p53 transcription factors in cells exposed to high doses of ionizing radiation [RNA-Seq] 0.52
Genomic profiling of human spermatogonial stem cells [BulkRNA-Seq] 0.51
Transcriptional change of THP-1 after HSV-1UL37WT or HSV-1UL37C819S 0.51
Gene expression changes in THP1 cells at day 2 and 4 following shRNA knock-down of RUVBL2 0.51
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression 0.5
Expression analysis of THP1 cells following shRNA knock-down of RUVBL2 0.49
Polyol pathway links glucose metabolism to the aggressiveness of cancer cells 0.49
Transcription profile analysis of wild type and Irf9-/- human monocytic THP1 cells in response to type I interferons 0.48
Irf9 function in immunity in mouse 0.48
A novel RAF kinase inhibitor with DFG-out binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation 0.47
Mitochondrial phosphoenolpyruvate carboxykinase (PCK2) regulates metabolic adaptation and glucose-independent tumor cell growth 0.46
Highly-motile versus unsorted MDA-MB-231 breast cancer cells 0.46
Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing [RNA-Seq] 0.46
Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing 0.46
Gene expression profile in breast cancer cell lines using RNA sequencing 0.45
Spliceosomal disruption of the non-canonical BAF complex in cancer 0.44
Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation II 0.44
Whole-Transcriptome Profiling of Canine and Human in Vitro Models Exposed to a G-Quadruplex Binding Small Molecule 0.44
Interactions of aCPs with Cytosine-rich Polypyrimidine Tracts Enhance Splicing of Cassette Exons 0.43
p53 activity results in DNA replication fork processivity 0.43
Inhibition of H3K4 demethylation induces autophagy in cancer cell lines 0.43
Gene expression profiling associated with knockdown of LKB1 in human intrahepatic cholangiocarcinoma 0.41
Transcriptional effect of ETV1 knockdown in melanoma cells 0.41
The CDK7 Inhibitor THZ1 Alters RNA Polymerase Dynamics at the 5’ and 3’ Ends of Genes 0.41
Nucleotide stress induction of HEXIM1 suppresses melanoma by modulating cancer cell-specific gene transcription [RNA-Seq1] 0.39
Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α 0.39
Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes 0.38
CRISPR/Cas9-mediated ASXL1 mutation in U937 cells perturbs myeloid differentiation 0.38
ENCODE Cold Spring Harbor Labs Long RNA-seq 0.37
Transcription elongation regulates genome 3D structure 0.37
Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner 0.35
The expression profiles of GBC liver metastasis 0.34
Modeling genome-wide transcriptional cis-regulation in n LNCaP-abl cell line after siRNA knock down of a series of gene factors [RNA-seq] 0.34
Gene expression and genome-wide location analysis of breast cancer cell-lines 0.33
Gene expression analysis of breast cancer cell-lines 0.33
A next generation sequencing based approach to identify extracellular vesicle mediated mRNA transfers between cells 0.33
Functional TRIM24 degraders via conjugation of ineffectual bromodomain and VHL ligands [RNA-seq] 0.33
Mitotically associated long non-coding RNA, MANCR regulates cell cycle in triple negative breast cancer cells  0.32
Patient-derived xenograft platform for metastatic melanoma 0.32
The DNA methylation landscape of human melanoma 0.32
The DNA methylation landscape of human melanoma [RNA-Seq] 0.32
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 1) 0.31
Gene expression for surgically treated pancreatic cancer after one neoadjuvant vaccine dose 0.31
RNA-seq analysis of control and ZC3H18-depleted ovarian cancer cells 0.31
Single cell transcriptomics reveals new insights on the dynamical function of transcription factors during blood stem and progenitor cell formation 0.3
Single-cell RNAseq analysis of the empty and i8TF cell lines after 3 days of BL-CFC culture 0.3
Translating transcriptome of cancer cells in situ in mesenchymal-rich tumor microenvironment 0.3
Transcriptome sequencing of K-562 cells 0.28
The RNA-binding protein RBM47 suppresses metastatic breast cancer progression 0.28
Transcriptome Analysis Reveals Distinct Responses to Physiologic versus Toxic Manganese Exposure in Human Neuroblastoma Cells 0.28
Quantitative profiling of the UGT transcriptome in human drug metabolizing tissues [Total RNA] 0.28
Expression changes in melanoma cell lines pre MAPKi treatment vs. post-MAPKi resistance (RNA-seq_CellLine.batch2) 0.27
circ-ZNF609 regulates G1-S progression in Rhabdomyosarcoma 0.27
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells [RNA-seq] 0.26
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells 0.26
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 0.25
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 0.25
Gene expression of collecting duct carcinoma of the kidney 0.25
RNASeq of 4SU labelled nascent RNA in MV4;11 cell treated with DMSO, I-BET, SGC0946 and combination of I-BET and SGC0946 0.25
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia [inhibitor MRT199665] 0.25
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer 0.24
Exploring the gene expression profile upon FXR1 knockdown in H358 cells using RNA-seq 0.24
Activation of Wnt/beta-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states 0.23
Leucegene: AML sequencing (part 6) 0.22
Gene expression regulated by CSA and CSB in neuroblastoma cell line 0.22
Effect of hyper-and hypoactivation of Notch signaling in IL-4-stimulate THP-1 0.2
Identification of differentially spliced genes by wild type or S34F mutation of U2AF1 0.2
MicroRNA-125a-5p overexpression in human macrophages 0.19
RNA-sequencing of tamoxifen-resistant and -sensitive breast cancer cell lines. 0.18
LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia 0.17
LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia (RNA-Seq) 0.17
Analysis of transcriptome changes following SOX2 knockdown in three different Ewing sarcoma cell lines 0.16
RNA-seq analysis of BORIS/CTCFL knockdown in K562 cell line 0.16
RNA-seq and small RNA-seq analysis of BORIS/CTCFL knockdown in K562 cell line 0.16
RNA-seq of SCLC PDX models treated with EP 0.16
Transcriptomic analysis of ERR alpha orphan nuclear receptor 0.16
Role of BET proteins in YAP/TAZ-dependent transcription [RNA-seq 1] 0.15
siRNA-mediated knockdown 0.15
The splicing factor RBM25 controls MYC activity in Acute Myeloid Leukemia 0.14
Role of NuRD subunits CHD3 and CHD4 in human melanoma cells (RNA-seq) 0.13
Role of NuRD subunits CHD3 and CHD4 in human melanoma cells 0.13
A RUNX2-mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells 0.12
RNA-seq of MDA-MB-231 cells with TET1 knockout 0.11
The effect of slow and rapid H2S production on the levels of LPS-induced proinflammatory mediators and transcription in different human cell cultures 0.11
Epithelial-mesenchymal transition markers screenedina cell-based model and validated in lung adenocarcinoma 0.1
The Wnt/β-catenin and RAS-ERK Pathways were Activated in Tissues of Chemotherapy-Resistant Gastric Cancer PDX Tumor 0.1
The ETS transcription factor ELF1 regulates a critical, broadly antiviral program distinct from the type I interferon response 0.09
The ETS transcription factor ELF1 regulates a critical, broadly antiviral program distinct from the type I interferon response 0.09
To identify transcripts that are differentially expressed in the MYCN amplified vs MYCN non-amplified cell lines using Next Generation Sequencing 0.09
Gastrointestinal Stromal Tumor Enhancers Support a Transcription Factor Network Predictive of Clinical Outcome 0.09
Gastrointestinal Stromal Tumor Enhancers Support a Transcription Factor Network Predictive of Clinical Outcome 0.09
Myc activation coordinates gene transcription and protein translation responses 0.08
LIN28A modulates splicing and gene expression programs in breast cancer cells [RNA-Seq] 0.06
LIN28A modulates splicing and gene expression programs in breast cancer cells 0.06
Expression changes in MAPKi resistant M229 melanoma lines co-cultured with PD-1 overexpressing HEK293T cells [CellLine.FPKM.batch5] 0.06
Nuclear Actin Regulates Inducible Transcription by Enhancing RNA Polymerase II Clustering 0.06
A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma 0.05
Interleukin-1β induces mitochondrial DAMP production to activate STING-dependent innate immune programs 0.05
Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells 0.04
Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer 0.03
RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer 0.02
A systematic analysis of the time series gene expression in TGF-beta induced EMT by Next-generation sequencing 0.01
The Wnt/β-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth 0.01
A novel Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia [RNA-Seq II] 0.01


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation